The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
NCT00438789 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2014-05-06
Summary
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
Conditions
- Hemoglobinuria, Paroxysmal
Interventions
- DRUG
-
600mg IV every week and 900mg IV every 2 weeks
Sponsors & Collaborators
-
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT04469465 ·Status: COMPLETED ·Phase: PHASE3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT00112983 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01335165 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07266155 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
NCT06593938 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT05389449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06238544 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06051357 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06100900 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06978699 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
NCT01977482 ·Status: COMPLETED ·Phase: PHASE2
-
Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients
NCT05699109 ·Status: COMPLETED
-
Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
NCT01881503 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
NCT06983756 ·Status: NOT_YET_RECRUITING
-
Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?
NCT03731741 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
NCT00701714 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
NCT01977573 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Pentoxifylline on Anemia in Hemodialysis Patients
NCT05708248 ·Status: UNKNOWN ·Phase: NA
-
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
NCT02648347 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients
NCT00666835 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07256301 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients
NCT00261521 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison Among Erythropoietin Stimulating Agents
NCT02049346 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients
NCT06115421 ·Status: UNKNOWN ·Phase: PHASE4